Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers

Biomark Med. 2022 Apr;16(5):349-369. doi: 10.2217/bmm-2021-0682. Epub 2022 Feb 23.

Abstract

Recently, long intergenic non-protein coding RNA 01133 (LINC01133) was identified as a novel transcript in cancers. It modulates various hallmarks of cancers and acts as oncogenic in some cancers while tumor-suppressive in others. Furthermore, the expression of LINC01133 correlates with tumor size, advanced tumor node metastasis stage and lymphatic node metastasis, Ki-67 levels and overall survival of patients. Herein, the authors provide an in-depth analysis describing how LINC01133 modulates the multiple cancer-associated signaling pathways and the pathogenesis of various malignancies and treatment regimens. Based on the role played by LINC01133, the authors propose LINC01133 as both a potential biomarker and a therapeutic target in cancer.

Keywords: LINC01133; cancer biomarkers; diagnosis; lncRNA; long non-coding RNA; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers
  • Biomarkers, Tumor / genetics
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lymphatic Metastasis
  • Neoplasms* / diagnosis
  • Prognosis
  • RNA, Long Noncoding* / genetics
  • RNA, Long Noncoding* / metabolism

Substances

  • Biomarkers
  • Biomarkers, Tumor
  • RNA, Long Noncoding
  • long non-coding RNA LINC01133, human